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Ever since the discovery of free radicals, many hypotheses on the deleterious actions of reactive oxygen species (ROS) have been
proposed. However, increasing evidence advocates the necessity of ROS for cellular homeostasis. ROS are generated as inherent
by-products of aerobic metabolism and are tightly controlled by antioxidants. Conversely, when produced in excess or when
antioxidants are depleted, ROS can inflict damage to lipids, proteins, and DNA. Such a state of oxidative stress is associated with
many pathological conditions and closely correlated to oxygen consumption.Although the deleterious effects of ROS can potentially
be reduced by restoring the imbalance between production and clearance of ROS through administration of antioxidants (AOs),
the dosage and type of AOs should be tailored to the location and nature of oxidative stress. This paper describes several pathways
of ROS signaling in cellular homeostasis. Further, we review the function of ROS in cardiovascular pathology and the effects of
AOs on cardiovascular outcomes with emphasis on the so-called oxidative paradox.
1. Introduction
In the mid 1950s, free radicals were first proposed to be
involved in the pathophysiology of a number of diseases [1].
However, due to their short life span and the technical dif-
ficulty of detecting them, it took till the 1980s to recognize
the importance of reactive oxygen species (ROS) as important
players in biological systems [2]. Nowadays, it is widely
accepted that ROS play a crucial physiological role, not only
in various diseases, but also in cellular homeostasis [3].
ROS are chemically reactive molecules derived from
molecular oxygen and formed as a natural by-product of
aerobicmetabolism. During energy conversion, ROS are pro-
duced as a by-product of oxidative phosphorylation, which is
presumed to be the major source of superoxide (O
2
∙−) pro-
duction [4, 5]. ROS can also be produced through a variety of
enzymes including xanthine oxidase and NAD(P)H oxidase
[3].
Under normal circumstances, ROS concentrations are
tightly controlled by antioxidants, keeping them in the pico-
molar range [3]. These low concentrations of ROS enable
their role as second messengers in signal transduction for
vascular homeostasis and cell signaling. When excessively
produced, or when antioxidants are depleted, ROS can inflict
damage onto lipids, proteins, and DNA. This intracellular
reduction-oxidation imbalance, called oxidative stress, can
subsequently contribute to the development and/or pro-
gression of cardiovascular diseases such as atherosclerosis,
ischemia-reperfusion injury, chronic ischemic heart disease,
cardiomyopathy, congestive heart failure, and even ensuing
arrhythmias [2, 6–8].
Apparently, within cellular physiology there is a paradox-
ical role for ROS, which is temporally and spatially defined.
In this paper we will discuss this dual role by summarizing
the aspects of ROS generation and metabolization in the
cardiovascular system, with focus on the role of ROS in
cardiovascular cell signaling, in particular hydrogen peroxide
(H
2
O
2
). In addition, we will discuss the role of ROS in
ischemic heart disease.
2. Molecular Basis of ROS
ROS encompass free radicals, oxygen ions, and peroxides,
both organic and inorganic, but all derived from molecular
oxygen. They are formed as necessary intermediates in
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a variety of normal biochemical reactions [3]. Only when
produced in excess or not appropriately controlled, they can
inflict damage within the body.
A division can be made into two groups: free radicals and
other ROS. Free radicals have an extremely high chemical
reactivity due to the unpaired free electron (i.e., superoxide
anion O
2
∙− and hydroxyl radical OH∙). Other ROS like H
2
O
2
and peroxynitrite (ONOO−) are not considered free radicals
as they lack the free unpaired electron and thus have oxidizing
rather than reactive effects [3, 9].
2.1. Formation of 𝑂
2
∙−. Within living cells, O
2
∙− is pro-
duced through two distinct pathways, namely, enzymatically
(Figure 1) and nonenzymatically. The latter occurs when a
single electron is directly transferred to oxygen by reduced
coenzymes or prosthetic groups (e.g., flavins or iron sulfur
clusters).
For most tissues, the primary source of O
2
∙− is situated in
the mitochondrial electron transport chain. It contains sev-
eral redox centers that may leak approximately 1%-2% of the
electrons to oxygen [5, 10]. Enzymatically, O
2
∙− is produced
from a variety of substrates, through different enzymes, most
importantly NAD(P)H (nicotinamide adenine dinucleotide
phosphate) oxidases, xanthine oxidases, and endothelial
nitric oxide synthase (eNOS), as will be discussed below
[11].
NADPH/NADH oxidases, located on the cell membrane
of polymorphonuclear cells, macrophages, and endothe-
lial cells, play an important role in generation of O
2
∙−
[3, 9]. Under normal circumstances, NAD(P)H oxidases
catalyze the reaction of NAD(P)H, H+, and oxygen to form
NAD(P)+and H
2
O
2
. These oxidases are mainly present in
adventitial fibroblasts but in different vascular pathologies,
such as atherosclerosis and hypertension; upregulation of
NAD(P)H expression has been shown in endothelial and
vascular smooth muscle cells [12].
The conversion of xanthine dehydrogenase to xanthine
oxidase (XO) provides another enzymatic source of O
2
∙− and
H
2
O
2
, which in turn constitutes a source of OH∙. The relative
amounts of O
2
∙− and H
2
O
2
formed by XO depend on the
conditions. At physiological oxygen concentrations between
10%, and 21%, H
2
O
2
constitutes about 75% of ROS formed,
whereas at lower oxygen concentrations, H
2
O
2
formation
from XO approaches 95% [13].
The oxidase itself converts hypoxanthine into xanthine
and xanthine into uric acid. Normally this process accounts
for a small part of the ROS production but under pathological
conditions, it has been proposed to mediate deleterious pro-
cesses in vivo. For example, after reperfusion, large quantities
of XO are released into the circulation possibly reacting with
plasma purine substrates and molecular oxygen to produce
ROS [14]. Chemical reactions forming molecular oxygen
throughNAD(P)H and xanthine oxidases are summarized in
(1)–(4), respectively.
NAD(P)H oxidase reaction :
NAD(P)H + 2O
2
󳨀→ NAD(P)+ + 2O
2
∙−
+ 2H−
(1)
Xanthine oxidase (XO) reaction :
Hypoxanthine +H
2
O + 2O
2
󳨀→ Xanthine + 2O
2
∙−
+ 2H−
(2)
Xanthine +H
2
O + 2O
2
󳨀→ Uric acid + 2O
2
∙−
+ 2H− (3)
(Hypo)Xanthine +H
2
O +O
2
󳨀→ Urate +H
2
O
2
. (4)
Within vascular pathology, a potential important source
of O
2
∙− can be attributed to endothelial nitric oxide synthase
[15]. There are three NOS isoforms, neuronal NOS (nNOS),
endothelial NOS (eNOS), and inducible NOS (iNOS). In
most cardiovascular tissues, nNOS and eNOS are consti-
tutively present [3]. NOS enzymes normally catalyze the
conversion of L-arginine to L-citrulline and produce nitric
oxide (NO). eNOS is a heterodimer with both reductase and
oxygenase domains on each monomer. In order to produce
NOvia eNOS, electronsmust be transferred from the cofactor
NAD(P)H to flavin adenine dinucleotide and flavin adenine
mononucleotide to heme.The electron flow through eNOS to
L-arginine, resulting in the production of NO, is dependent
on the availability of its cofactors [16].
The balance between nitric oxide (NO) and O
2
∙− pro-
duction is regulated by the availability of tetrahydrobiopterin
(BH
4
). BH
4
is involved in the catalytic process of L-arginine
oxidation [17]. With impaired bioavailability of BH
4
, O
2
∙− is
released rather than NO, a condition referred to as “eNOS
uncoupling” [15] (Figure 2), where electrons that normally
flow from the reductase domain to the heme group, now
divert towards molecular oxygen rather than L-arginine [15,
18]. In vascular disease, amajor part of this catalytic enzyme is
uncoupled due to BH
4
deficiency.The consequent increase in
O
2
∙− rapidly reacts with NO to form peroxinitrite (ONOO−).
ONOO− oxidizes BH
4
leading to “eNOS uncoupling,” and
more production of O
2
∙−, thereby creating a vicious circle of
ROS induced ROS production [15]. As will be discussed later
on, the resulting endothelial dysfunction disturbs normal
vascular responses and is associated with the development
of atherosclerosis [11]. Importantly, endothelial dysfunction
has been shown to be a prognostic factor for progression of
atherosclerotic disease as well as cardiovascular event rate
[19].
2.2. Reduction of 𝑂
2
∙−. Oxidation-reduction reactions are
highly similar to acid-base reactions and concern the transfer
of electrons. The key in these reactions is that electrons
are exchanged between reaction partners and not shared as
with covalent bindings. Oxidation-reduction reactions are
matched set, meaning that for every oxidation reaction there
is simultaneous reduction reaction and are therefore called
“half-reactions.”
Oxidation refers to loss of electrons, while reduction
denotes the gain of electrons.The change of electrons between
partners can be predicted by using the oxidation number,
which is the algebraic difference between the number of
protons and electrons in a specific ion. The produced inter-
mediates are able to oxidize (by donating electrons) several
molecules. When oxygen is scarce, cells move to a more
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Figure 1: Summary of production and removal of various reactive oxygen species. Superoxide (O
2
∙−) can dismutate in several ways, either
spontaneously through a reaction with superoxide dismutase (SOD), through the Haber-Weiss reaction, or in reaction with nitric oxide (NO)
and its radical (NO∙). Through SOD, hydrogen peroxide (H
2
O
2
) is formed and further reduced by catalase and peroxidase to form water and
oxygen. Also, H
2
O
2
can be formed directly from xanthine oxidase. The hydroxyl radical (OH∙) is formed through the Haber-Weiss reaction,
through the Fenton reaction, and from peroxynitrous acid (HOONO). O
2
∙− can also scavenge NO to form peroxynitrite (ONOO−) leading
to nitroso-redox imbalance. NADH/NADPH oxidase: nicotinamide adenine dinucleotide (phosphate); (e)NOS: (endothelial) derived nitric
oxide synthetase; NO: nitric oxide, NO
2
: nitric dioxide; mitoch. Oxidat. phosphor, mitochondrial oxidative phosphorylation; dotted lines:
inhibition.
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Figure 2: eNOS uncoupling. Excess superoxide (O
2
∙−) production,
for example, after myocardial infarction, results in scavenging of
nitric oxide (NO) to form peroxinitrite. The latter inhibits coupling
of not only endothelial derived nitric oxide synthetase (eNOS)
and tetrahydrobiopterin (BH
4
), but also L-arginine and superoxide
dismutase (SOD), which creates a downward spiral of enhanced
O
2
∙− production. Finally, eNOS gets uncoupled and produces O
2
∙−
rather than NO, sustaining the loop of nitroso-redox imbalance.
reduced state resulting in altered function of biomolecules.
This redox signaling comprises oxireductive chemical reac-
tions that alter proteins posttranslationally, thereby creating
a coupling between redox state and cell function [6].
O
2
∙− can dismutate (be reduced) in several ways (Fig-
ure 1), either spontaneously through a reaction with super-
oxide dismutase (SOD), through the Haber-Weiss reaction,
or in reaction with NO. O
2
∙− has a half-life of 10−9 to 10−11 s
while in the presence of SOD, the half-life decreases to 10−15 s.
The reaction catalyzed by SOD reduces two O
2
∙− radicals to
form oxygen and H
2
O
2
which in turn can be fully reduced to
H
2
O and oxygen:
2O
2
∙−
+ 2H+ 󳨀→ H
2
O
2
+O
2
. (5)
H
2
O
2
is oxidized by peroxidase and catalase. It has a half-
life of 10−3 s in the absence of catalase and 10−8 s in its
presence. Alternatively, H
2
O
2
can react with reduced transi-
tion metals—called the Fenton reaction—to form OH∙ and
OH− or OOH∙ and H+, when combined with Fe2+ or Fe3+,
respectively [3]:
Fe2+ +H
2
O
2
󳨀→ Fe3+ +OH∙ +OH− (6)
Fe3+ +H
2
O
2
󳨀→ Fe2+ +OOH∙ +H+. (7)
The typical range for the iron dose is 1 part of Fe per 5–25
parts of H
2
O
2
. The optimal pH for the Fenton reaction is
between 3 and 6. When the pH is too high, iron precipitates
in Fe(OH)
3
and will decompose H
2
O
2
into oxygen. The
Fenton reaction occurs predominantly at the endoplasmatic
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reticulumbut not atmitochondria or other intracellular com-
partments [20]. Liu and coworkers showed that the Fenton
reaction is involved in oxygen sensing, through regulation
of genetic expression of hypoxia inducible factor-1 (HIF-1)
[20]. An important role of HIF-1 is to establish the optimal
balance between glycolytic and oxidative metabolism at any
oxygen concentration to maximize ATP production without
increasing ROS levels. Thus, HIF-1 induces metabolic repro-
gramming in cells that are oxygen deprived, thereby reducing
mitochondrial respiration, minimizing O
2
∙− production [21],
and contributing to a fast responding oxygen-sensing system.
The reaction of O
2
∙− with NO∙, controlled by the rate
of diffusion of both radicals, forms the very potent oxidant
ONOO−. ONOO− in turn is oxidized or reacts with a
hydrogen radical (H∙) to form the stable HOONO. The lat-
ter dismutates quickly into OH∙ and free nitrogen species
(NO
2
∙). Thus concentrations of OH∙ increase by means of
H
2
O
2
and HOONO dismutation (metal independent path-
way). Alternatively, OH∙ can be generated through the
Haber-Weiss reaction, when superoxide radicals and H
2
O
2
molecules spontaneously combine to formmolecular oxygen
and hydroxyl radicals:
O
2
∙−
+H
2
O
2
󳨀→ OH∙ +OH− +O
2
. (8)
3. ROS and Cell Signaling
3.1. Signal Transduction Pathways of Cellular Responses to
ROS. Most cells have been shown to generate a small burst of
ROS when stimulated by, for example, cytokines, angiotensin
II (Ang II), endothelin-1 (ET-1), and platelet derived growth
factor (PDGF) [22], leading to the hypothesis that ROS play
an important role in cellular homeostasis and communi-
cation [3] (Figure 3). ROS signaling involves alterations in
the intracellular redox state and oxidative modification of
regulatory and contractile proteins (Figures 4–5).
The intracellular redox state within cellular homeostasis
is primarily balanced by the glutathione/glutathione disulfide
couple which functions as a major redox buffer, indicating/
determining the redox state of the cell [23]. Glutathione
(GSH) is abundantly present in the cytosol, nucleus, and
mitochondria. It is synthesized in the cytosol and transported
to the mitochondria and the nucleus [24]. GSH exhibits
protection against ROS by (a) participating in amino acid
transport through the plasma membrane, (b) scavenging
OH∙, H
2
O
2
, and lipid peroxidases via glutathione peroxidase
(GPx) (catalytic reaction), (c) being a cofactor in numerous
detoxifying enzymes (e.g., GPx), and (d) regeneration of the
most important AOs back to their active form [25].The latter
function is linked with the redox balance of GSH with its
oxidized form GSSG [26].
Glutathione exists in reduced (GSH) and oxidized
(GSSG) states. When reduced, the thiol group of cysteine
can donate a reducing equivalent to other unstable molecules
such as ROS. By doing so, glutathione itself becomes reactive
and quickly reacts with another reactive glutathione to form
glutathione disulfide (GSSG). Once oxidized, glutathione can
be reduced back by glutathione reductase, thereby using
NAD(P)H as an electron donor. Under normal physiological
ROS
AO
[ROS]
LowHigh
Oxidative
stress
Cell
signaling
Figure 3: Redox balance.The production of reactive oxygen species
(ROS) is tightly controlled by antioxidants (AOs) keeping the con-
centration of ROS ([ROS]) in the picomolar range. This low [ROS]
is necessary for adequate cell physiology. When ROS is excessively
produced or AOs are depleted, there is a high intracellular [ROS]
leading to oxidative stress and resulting in cellular damage.
conditions, more than 90% of the glutathione in the cell is
in the reduced form (GSH) and less than 10% exists in the
disulfide form. An increase in GSSG/GSH ratio, for example
due to inactivation of glutathione reductase by ONOO−, is
considered to be indicative of oxidative stress [27].
ROS can posttranslationally modify proteins. Redox sig-
naling typically involves amino acid oxidation, hydroxyla-
tion, or nitration. Targets usually are redox sensitive cysteine
residues within the proteins, which have a low ionization pKa
of 4-5 compared to a pKa of 8.5 of nonreactive cysteines in
other proteins [28, 29]. The modifications in these redox
sensitive proteins alter their conformation, stability, activity
and/or ability to interact with other proteins, resulting in
modulation of cellular function. Redox sensitive proteins
include proteins involved in calcium handling as well as
contractile proteins, proteins involved in various signaling
pathways and proteins involved in transcriptional activities.
Redox modulation of calcium handling proteins directly
affects cardiac contraction by altering intracellular calcium.
Examples of redox sensitive calcium handling proteins are
calcium calmodulin kinase II (CaMKII), the ryanodine
receptor on the sarcoplasmic reticulum, sarcoplasmic retic-
ulum ATPase (SERCA), and phospholamban (for review
see [29, 30]). Moreover, the contractile proteins can also
be oxidatively modified by oxidation or nitrosylation [30].
Typically, oxidation of contractile proteins is assumed to
depress cardiac function, although recently some modifica-
tions have been identified that actually increase contractility.
The current understanding onhowoxidative stressmodulates
cardiac function is limited mostly because many studies have
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Figure 4: ROS production and vascular signaling. Several mechanical as well as circulating factors can increase ROS concentrations by acting
on the tunica intima. The increased amounts of ROS activate specific second messenger systems which finally convey a cellular response.
Hchol: hypercholesterolemia; DM: diabetes mellitus; IA: infectious agents; HC: homocysteine; MC: monocyte; GF: growth factors (PDGF,
IGF-1, EGF, etc.); Cytokines (IL-1, TNF-𝛼, etc.); oxLDL: oxidized low-density lipoprotein; eNOS: endothelial derived nitric oxide synthetase;
PK: protein kinase A/C/G.
focused on isolated myofilament proteins whereas oxidative
modifications of different contractile proteins occur simulta-
neously in vivo and act in concert.Hence, the contributions of
the individual oxidative modification are difficult to establish
[30].
The second group of proteins affected by direct redox
modification are protein kinases and phosphatases. Since
tyrosine phosphorylation is an early signaling event in many
signal transduction pathways, alterations in activity through
redoxmodification of protein kinases upstream in the signal-
ing cascade result in indirect modulation of protein kinases
more downstream in the cascade. Tyrosine phosphorylation
in vascular smooth muscle cells is important in the control of
vascular tone.Thus, tyrosine phosphatase inhibitors generally
constrict smooth muscle, whereas tyrosine kinase inhibitors
cause relaxation [28]. Oxidative modification results in inhi-
bition of phosphotyrosine phosphatases (PTP 1A, PTP1B,
and PTEN), while the protein kinase Src is activated by
oxidation. Src has many targets in the cell. Interestingly, Src
activates receptor tyrosine kinases such as the EGF-receptor
in vascular smooth muscle cells. This activation occurs
independent of EGF, and the activated receptor then acts
as a signaling platform for the stimulation of phospholipase
enzymes, production of lipid mediators, and activation of
downstream kinases such as PI3K, Akt, ERK, and PKC [28].
PKC is directly activated by oxidation of the cysteine
residues in its regulatory site, which occurs at low concen-
trations of oxidants. Conversly, PKC is inhibited by oxidation
of cysteine residues in its catalytic domain, which occurs
at higher concentrations of oxidants. Alterations in PKC
activity affect many signaling cascades in the cell, including
modulation of calcium sensitivity of the myofilaments and
receptor tyrosine kinase signaling [28, 30].The cAMP-depen-
dent protein kinase A (PKA) and the cGMP-dependent pro-
tein kinase G (PKG) are also susceptible to redox modifi-
cation. Both PKA and PKG are involved in regulation of
vascular tone as well as cardiomyocyte contraction. When
PKA oxidation occurs in its regulatory domain, it promotes
dissociation of the catalytic and regulatory subunits resulting
in cAMP independent PKA activation [29, 30]. However,
similar to PKC, oxidation of cysteine residues in the catalytic
subunit inhibits PKA activity [29]. Oxidation of PKG in
its dimerization domain results in activation of the enzyme
independently of the NO-cGMP pathway [29]. Oxidative
modification of PKA, PKC, and PKG results in altered phos-
phorylation of the myofilaments, thereby modulating cardiac
as well as vascular function.
The small monomeric G-proteins ras, rac-1, and RhoA
are also activated by ROS. Activation of RhoA results in
its translocation to the plasma membrane and activation of
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Figure 5: Different pathways leading to cell injury after ischemia. Ischemia due to atherosclerotic obstruction leads to an inflammatory
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Rho-kinase. Rho-kinase appears to be a key player in car-
diovascular function and cardiovascular pathology. Thus, in
vascular smooth muscle cells, Rho-kinase regulates calcium
sensitivity of the myofilaments via inhibition of myosin light
chain phosphatase [31]. Moreover, activation of Rho-kinase
contributes to smooth muscle proliferation, hypertrophy
and motility [32]. Rho-kinase activation is responsible for
upregulation ofNAD(P)H oxidases, thereby contributing to a
vicious circle of ROS, leading to Rho-kinase activation result-
ing inmore ROS production. In endothelial cells, Rho-kinase
negatively regulates NO-production both by destabilizing
eNOS mRNA and through impairment of eNOS activity [31,
32], thereby also contributing to augmentation of oxidative
stress. In cardiomyocytes the role of Rho-kinase is less well
understood although it is thought to function in a similar way
to its role in vascular smoothmuscle. In addition, Rho-kinase
is thought to be involved in cardiomyocyte hypertrophy and
apoptosis [31]. Yet, the precise role of Rho-kinase, as well as its
modulation by redox regulation in cardiacmyocytes, remains
to be determined.
Another group of kinases that are not directly redox sen-
sitive but very important in cardiovascular cell signaling
are mitogen-activated protein kinases (MAPKs) (Figure 4).
MAPKs are indirectly activated by ROS via the ROS sensitive
kinases Src, PKC, ras, and the MAPK kinase kinase ASK-1
[33]. MAPKs are divided into three subgroups: extracellular
signal regulated kinases (ERKs): ERK1 and ERK2; c-Jun N-
terminal kinases (JNKs): JNK1, JNK2, and JNK3; and p38
kinases: p38 𝛼, 𝛽, 𝛾, and 𝛿 [3, 34, 35]. In addition to
being indirectly activated by ROS, MAPKs are activated by
environmental stresses and inflammatory cytokines, which
are also known to induce oxidative stress.
The third important group of redox sensitive proteins in
the cardiovascular system are the proteins involved in tran-
scriptional activity, not only including transcription factors
but also histone deacetylases (HDAC). ROS can both inhibit
and stimulate cellular NF-𝜅B signaling [36], while certain
NF-𝜅B regulated genes play a major role in regulating the
amount of ROS in the cell. Also, recently ROS have been
shown to directly connect the important redox sensitive
transcription factors NF-𝜅B and HIF-1, implicating a novel
signaling pathway in cardiovascular pathology (Figure 5)
[37].
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Histone acetylation by histone acetylases promotes gene
expression, while histone deacetylation by HDACs inhibits
gene expression. Oxidation of HDAC4 and HDAC5 that are
expressed in cardiac myocytes results in export of these
HDACs from the nucleus, thereby inhibiting their activity. As
these HDACs normally inhibit the transcription of prohyper-
trophic genese their oxidation may be involved in induction
of hypertrophy [29].
The long-term consequences of ROS for cardiovascular
(dys)function depend on the balance between signals pro-
moting proliferation or growth inhibition and/or cell death.
ROS can alter this balance leading to either excessive angio-
genesis or loss of endothelial cells [2]. The dual role of ROS
in “fine-tuning” the balance between apoptosis and exces-
sive cell growth is illustrated by observations that, during
ischemia-reperfusion injury, ROS trigger apoptosis, while
ROS generated during ischemic preconditioning prevent
apoptosis [38–41]. ROS generated during ischemic precon-
ditioning are capable of upregulating expression of the Bcl-2
gene [42], which regulates the intrinsic pathway of apoptosis
[43, 44]. This gene is also activated via the nuclear transcrip-
tion factorNF-𝜅B and its activation has been shown to reduce
apoptosis [42, 45].
Conversely, endothelial apoptosis initiated by tumor nec-
rosis factor-𝛼 (TNF-𝛼) and mediated by activation of JNK
can be attenuated by ROS scavenging [46]. TNF-𝛼 has
been implicated in inflammatory responses of the heart
and vasculature. Thus, TNF-𝛼 is one of the inflammatory
cytokines that are produced in the ischemic region and sur-
roundingmyocardium followingmyocardial infarction. Also,
vessels from subjects with diabetes are characterized by an
increasedTNF-𝛼 production, increasedROSproduction, and
endothelial dysfunction [47]. Similarly, endothelial dysfunc-
tion induced by advanced glycation end products (AGEs) is
mediated through elevated TNF-𝛼 expression and induction
of ROS production with NF-𝜅B functioning as the link
between TNF-𝛼 and AGEs/RAGE signaling [48, 49]. TNF-
𝛼 and NF-𝜅B are interrelated in that translocation of NF-𝜅B
into the nucleus has been proposed to be pro-inflammatory
and, either directly or indirectly, leads to a significant increase
in TNF-𝛼 production while TNF-𝛼 activates NF-𝜅B, which
then regulates genes involved in inflammation, oxidative
stress, and endothelial dysfunction [49, 50]. Interestingly,
ROS produced in response to TNF-𝛼 can further activate
NF-𝜅B which again activates TNF-𝛼 creating a vicious circle
[51]. Hence, ROS play a key role in the induction of vascular
dysfunction in response to TNF-𝛼 [47].
3.2. The Role of 𝐻
2
𝑂
2
in Signal Transduction. H
2
O
2
is an
interesting molecule within the ROS family. It is a waste
product of mitochondrial electron transfer and, hence to be
created, no additional energy is required.The chemical prop-
erties of H
2
O
2
, such as a short half-life, rapid metabolization
by catalase, and rapid reactionwith thiols, are ideal properties
for H
2
O
2
to act as a signaling molecule.
H
2
O
2
mediates diverse physiological responses including
cell differentiation, proliferation, andmigration, and has been
proposed to be involved in metabolic vasodilation [3, 70]. In
cells stimulated with growth factors and cytokines (PDGF,
EGF, insulin, TNF-𝛼, and interleukins), the NAD(P)H oxi-
dase gp91 Phox and homologues form the major source of
H
2
O
2
[34, 70–72]. However, the coupling between receptor
activation to the NAD(P)H oxidase complex (Nox) is still
poorly understood [73]. In order to mediate different res-
ponses, H
2
O
2
modifies the activity of key signaling proteins.
It catalyzes redox reactions, oxidizing primarily cysteine
residues of proteins thereby altering their function. For exam-
ple, the activity of tyrosine phosphatases is H
2
O
2
dependent.
The chemical configuration of these phosphatases contains a
cysteine and arginine site resulting in a low PKa and existing
as a thiolate anion. The latter is more susceptible to H
2
O
2
oxidation which abolishes its activity and is reversed by
cellular thiols [74]. Not only tyrosine phosphatase but also
tyrosine kinase (Src) is oxidized by H
2
O
2
[75]. An overall
regulation must exist, that is, both temporal and spatial,
ensuring process activation (only when and where needed)
and termination after exerting its effects.
In order to induce protein alterations, H
2
O
2
must
increase rapidly above a certain threshold, but each cell
contains natural AO enzymes.Therefore H
2
O
2
has to be pro-
tected from destruction. H
2
O
2
is inactivated by peroxire-
doxin, which is part of a family of antioxidant enzymes whose
thioredoxin peroxidase activity plays an important role in
protecting against oxidative stress [76]. Interestingly, H
2
O
2
causes hyperoxidation, and thereby inactivation, of peroxire-
doxin, prolonging H
2
O
2
bioavailability. The inactive perox-
iredoxin can be reactivated by the adenosine triphosphate-
dependent enzyme sulfiredoxin [77].
How H
2
O
2
is actually delivered to the cytosol remains
incompletely understood. H
2
O
2
must cross the lipid bilayer
towards the target molecules in the cytosol. Although it is
generally assumed that H
2
O
2
crosses the membrane freely,
recent research indicates some membranes to be poorly
permeable to H
2
O
2
[78]. A shift in membrane lipid compo-
sition or a transport through aquaporins was presented as an
alternative pathway to transfer H
2
O
2
molecules to the cytosol
[79]. Alternatively,H
2
O
2
may also pass through gap junctions
to exert its effect [80–82].
There is clearly a duality present in the role for H
2
O
2
in cell proliferation. On the one hand, low concentrations
of H
2
O
2
play an important role in regulating cell growth,
although the question remains if this effect is exerted merely
through second messengers (JAK/STAT) or if H
2
O
2
also has
a direct effect on growth. On the other hand, high con-
centrations of H
2
O
2
are responsible for cell apoptosis while
moderate doses cause the cell to arrest in the G1 phase [83].
Recently, H
2
O
2
-induced apoptosis was shown to bemediated
through a PKC-dependent pathway, antagonized by Akt and
heme oxygenase-1 [84]. Also, recent data support the hypoth-
esis that H
2
O
2
can function as a transmitter of the apoptotic
signal from the region of programmed cell death to neighbor-
ing healthy cells [85]. Apoptotic cells produce H
2
O
2
, thereby
possibly contributing to the pathogenesis of, for example
myocardial infarction and ageing. More specifically, mito-
chondrial produced ROS are needed for the generation of
the apoptotic signal since specifically designedmitochondrial
antioxidants (such as SkQs) inhibit this pathway [86].
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H
2
O
2
may also be involved in the response to vascular
injury. Vascular smooth muscle cell (VSMC) death has been
shown to occur after mechanical trauma like stenting. In
response to vascular injury, potent chemotactic factors, such
as bFGF, PDGF, TGF-𝛽, and Ang II, are released [2]. These
chemotactic factors in turn regulate VSM proliferation and
migration. Two independent research groups have shown
that this release of chemotactic factors is H
2
O
2
dependent
and thus reduced when administrating a scavenger like
catalase [87, 88]. The hypothesis for ROS involvement in
VSMC proliferation is further supported by a study showing
that catecholamine induced VSCM proliferation can be
blocked by N-acetylcysteine, tiron (superoxide scavenger),
and diphenylene iodonium [89]. To allow VSMC migration
and vascular remodeling, degradation of the extracellular
matrix is required, which is partially accomplished by matrix
metalloproteinases (MMPs). Both activity and expression of
MMP-2 and MMP-9, the two MMPs thought to be most
important in vascular remodeling, have been shown to be
regulated by the nitroso-redox balance. Thus, H
2
O
2
and
OONO− increase MMP-2 activity while reduction of MMP-
2 and MMP-9 can be obtained by overexpressing eNOS [90,
91]. Not only the activity of the MMP family is modulated
by ROS but also their expression, thereby providing a dual
mechanism for ROS to regulate vascular remodeling.
3.3. ROS and Pathophysiology (Figures 4 and 5). The mito-
chondrial respiratory chain is one of the most prominent
cellular sources of ROS. Hence, ROS production is related
to oxygen consumption, making cells with high oxygen
consumption more prone to oxidative stress. Oxygen con-
sumption is particularly high in cardiac myocytes that are
therefore equipped with a high number of mitochondria and
a high level of respiratory chain components per milligram
of mitochondrial protein. To prevent oxidative damage, these
cells contain enzymatic scavengers of ROS such as SOD,
glutathione peroxidase, catalase, and coenzymeQ10. Possibly
together with nonenzymatic AO, they neutralize the deleteri-
ous effects of ROS. Mitochondria also possess the ability to
repair themselves after oxidative damage using enzyme sys-
tems like phospholipid hydroperoxide glutathione peroxidase
(PHGP). PHGP is a selenium containing enzyme directly
reducing peroxidized acyl groups in phospholipids [92].
However, under pathological conditions, these protective
mechanisms may fall short and make the cardiac myocytes
vulnerable to oxidative damage.
With increased production of ROS, damage can be
inflicted directly via oxidative modification of redox sensitive
proteins [3, 10]. Also, inflammation, which in turn stimulates
the release of O
2
∙−, leads to cell injury, either directly or
by depleting the natural AOs. An overview of the systems
leading to cell damage via NO∙, ONOO−, O
2
∙−, H
2
O
2
/OH∙,
complement activation, and PARP activation is presented in
Figures 3, 4, and 5.
Some examples of how oxidative stress is involved in car-
diac and vascular pathologies are described in the following
sections.
3.4. Hypoxia, Ischemia, and Reperfusion. Medical strategies
treating acute myocardial infarction require restoration of
blood flow to the ischemic region. Unfortunately, this reper-
fusion is associated with a burst of ROS, which may continue
for hours [93], and recruitment of inflammatory cells [94,
95]. These high levels of ROS cause structural damage
of the heart, capillary leak, and influence cardiomyocyte
metabolism thereby impairing both systolic and diastolic
function [96]. Furthermore, not only ischemic damage, but
also reperfusion, can produce dysfunction of the cardiac
conduction system leading to arrhythmias [7, 97]. Besides
increased ROS production, hypoxia, ischemia, and reperfu-
sion have also been found to reduce levels of SOD, GSH,
glutathione peroxidase, and ascorbate [98]. Hence, reduced
scavenging further contributes to development of oxidative
stress.
Reperfusion also inflicts damage on the vascular endothe-
lium, with alterations in blood cells and microembolization,
as well as vascular compression due to myocyte swelling,
leading to changes in endothelial structure and alignment.
The duration of ischemia is an important determinant of the
extent of reperfusion damage. Ischemia-reperfusion damage
can be reduced by ischemic preconditioning [99]. The mech-
anisms underlying this protection by ischemic precondition-
ing are incompletely understood [100]. Yet, a role for ROS
as triggers for and mediators of this protective phenomenon
has been consistently demonstrated. ROS can trigger pre-
conditioning by causing activation of the mitochondrial
KATP channel, which then induces generation of ROS and
NO that are both required for preconditioning induced
protection [101–104]. Importantly, ischemic preconditioning
can be mimicked by administration of free radical donors S-
morpholinosydnonimine [105] and evenONOO− [106] while
preconditioning can be blocked by free radical scavengers.
Ischemic preconditioning is therefore a clear example
of the so-called oxidative paradox: AOs not only reduce
deleterious ROS accumulation but also molecules necessary
for cardioprotection.
3.5. Atherosclerosis. The majority of cardiovascular disease
is a direct consequence of atherosclerosis. The transfer of
oxidized low-density lipoprotein (ox-LDL) from the vessel
lumen into the tunica media is regarded as the initiator
for atherosclerosis at sites with endothelial damage [107].
Mechanical factors like fluid shear stress patterns play an
important role in maintenance of endothelial function and
initiation of endothelial dysfunction [3]. Thus, laminar shear
stress induces expression of AO genes and production of
NO∙, preventing apoptosis and monocyte adhesion [108].
Branched arteries exposed to oscillatory shear stress are
prone to atherosclerosis.This type of flow leads to continuous
NAPDH-dependent production of O
2
∙− [109, 110]. Increased
O
2
∙− can subsequently uncouple eNOS, thus creating an extra
source of O
2
∙− production and leading to a vicious circle
of ROS-induced ROS production. Upregulation of adhesion
molecules (VCAM-1, E-selectin, P-selectin, and ICAM-1)
[111] at locations with disrupted flow patterns is also ROS
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Table 1: Major studies with possible beneficial effects of AOs on cardiovascular outcomes in humans.
Author/study Journal Design/FU Population∗ Agents (dosage/day) Results
Stephens et al./
CHAOS [52] The Lancet
DB, PC
1.4 y
(3 d–3 y)
𝑁= 2002; M and F; mean
61.8 y; ischemic heart
disease patients; secondary
prevention
E (800mg or 400 IU) ↓↓ I nonfatal MI, trend ↑CV death
Duffy et al. [53] The Lancet DB, PC30 d
𝑁= 45; M and F; mean
48.5 y; HT patients C (500mg)
↓ BP in otherwise healthy
HT
Boaz et al./
SPACE [54] The Lancet
DB, PC
2 y
𝑁= 196; M and F; 40–75 y;
haemodialysis patients E (800 IU)
↓↓ combined endpoint of
AMI =CV death + stroke
Neri et al. [55] ClinicalTherapeutics
DB, PC
15 d
𝑁= 46; M and F; mean
40 y; DM/glucose
intolerance patients
NAC (600 g) +C (250mg) + E
(300mg) ↓ OS and inflammation
Accini et al. [56]
Nutrition,
Metabolism and
Cardiovascular
Diseases
DB, PC
4m
𝑁= 57; M and F; 23–65 y;
dyslipidemic patients
E (4mg); PUFAn-3 (6602mg
EPA+ 440 DHA); niacin
(18mg); 𝛾OZ (40.2mg)
↓ OS and inflammation
markers
The CHAOS study is the largest study to report a strong decrease in nonfatal MI but, conversely, a slight increase in cardiovascular death. Other studies were
performed in smaller groups. Overall, no overwhelming positive effects could be found in the studies. Population∗:𝑁: number of patients;M:male; F: female; y:
age in years. DB: double blind; PC: placebo controlled; d: days; m: months; E: vitamin E; C: vitamin C; NAC: N-acetylcysteine; PUFAn-3: polyunsaturated fatty
acids n-3; EPA: eicosapentaenoic; DHA: docosahexaenoic; 𝛾OZ: 𝛾-oryzanol; I: incidence; BP: blood pressure; CV: cardiovascular; MI: myocardial infarction;
HT: hypertension; AMI: acute myocardial infarction; OS: oxidative stress.
dependent and is further enhanced by cytokines like inter-
leukins, TNF-𝛼, Ang II, and vascular endothelial growth fac-
tor (VEGF) [3, 109–111]. Upregulation of adhesion molecules
facilitates adherence and transmigration of leucocytes (Fig-
ures 4 and 5). Once converted tomacrophages, they are capa-
ble of producing much higher amounts of ROS. ROS convert
ox-LDL into highly oxidized LDL which itself is engulfed
by these macrophages, forming foam cells and initiating the
formation of the fatty streak.
Overall, the amount and pattern of blood flow are very
important for endothelial function where aberrant flow pat-
terns predispose to ROS production and atherosclerosis.
3.6. Clinical Evidence for Therapeutic Use of Antioxidants?
The deleterious effects of ROS can be reduced by restoring
the imbalance between production and clearance of ROS
[112]. Gey and colleagues found low rates of cardiovascular
disease (CVD) in people consuming AO rich diets [113]. This
second line of defense includes nonenzymatic antioxidant
substances from dietary intake such as ascorbic acid (vitamin
C), 𝛼-tocopherol (vitamin E), GSH, flavonoids, carotenoids,
and others. In vitro studies indicated oxidation inhibition
of low-density lipoproteins (LDL) by a number of these
nonenzymatic AOs. Exogenous therapeutic administration
of antioxidants has therefore been proposed as therapy for
oxidative stress and cardiovascular disease. Despite some
promising effects of such AO administration (Table 1), partic-
ularly in animal studies, caution should be warranted as these
results could usually not be reproduced in clinical trials.Thus,
conflicting results on the use of dietary supplementation of
AOs, especially vitamin C, vitamin E, 𝛽-carotene, and sele-
nium, have been presented (Table 2). AO supplementation is
potentially deleterious for normal “redox homeostasis.” Not
only is the redox balance very delicate, but also ROS play
important roles in cell signaling and are therefore essential
for survival of the organism [3, 9, 114]. The most relevant
AOs used in dietary supplementation are flavonoids and
vitamins C and E. The beneficial cardiovascular effects of
these substances may not be limited to their AO effect, as
they also include anti-inflammatory, platelet inhibitory, and
antithrombotic effects.
One of the most studied AO supplements in prevention
of cardiovascular disease is vitamin E. Many studies suggest
a protective role for vitamin E, which has led to a massive
marketing of vitamin E supplements. Conversely, large ran-
domized studies (Table 2) could not substantiate this role
for vitamin E. Indeed, meta-analysis failed to find a cardio
protective effect nor did it find a reduction of clinical events in
high risk patients or in patients with established disease [115–
117]. Interestingly, a recent analysis even reports an increased
mortality after using supplements of 𝛽-carotene and vitamin
E [117].
When comparing Table 1 with Table 2, clinical trials fail to
show a protective effect of AOs in humans. Not only are the
positive outcome studies largely outnumbered by trials with
no effects, they are also, in most cases, lacking the statistical
power to be conclusive.The reason for failure of these AOs in
clinical practice is most likely multifactorial.
First of all, it is very difficult to detect subjects with
a comparable imbalance between ROS production and AO
defenses. Second, biochemical aspects inherent to each sub-
stance used, posology, and intake ratio must be taken into
account. The lack of knowledge of the optimal dosage and
route of administration for the various AOs is a serious
limitation. For example, the bioavailability of vitamin C is
determined by the availability of its transporter in the small
intestine, and an increase of oral administration of vitamin
C can actually decrease bioavailability [118]. This example
illustrates that pharmacodynamical and pharmacokinetical
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Table 2: Major studies with no beneficial effects of AOs on cardiovascular outcomes.
Author/study Journal Design/FU Population∗ Agents (dosage/day) Results
Hennekens et al./
physician health
[57]
The New
England
Journal of
Medicine
DB, PC, 2 × 2
12 y ( 𝛽C)
𝑁= 22.071; all M, 40–84 y;
former or current smokers 𝛽C (50mg) on alt days
No effect on CV death,
AMI, or all-cause mortality
Rapola et al.
[58] The Lancet
DB, PC
5.3 y
𝑁= 1862; all M; 50–69 y;
smokers with previous MI E (50mg) +𝛽C (20mg) No ↓ of MCE, ↑ risk FCHD
Virtamo et al.
[59]
Archives of
Internal
Medicine
DB, PC
6.1 y
𝑁= 27.271; all M; 50–69 y;
smokers, no MI history;
primary prevention
E (50mg) +𝛽C (20mg) E: ± ↓ I fatal CHD, no ↓ Inonfatal CHD; 𝛽C no effect
Italiano/GISSI
Prevenzione
Investigators
[60]
The Lancet OL, PC, 2 × 23.5 y
𝑁= 11.234, M and F;
stratified for all age groups;
AMI within 3 months;
secondary prevention
E (600mg) + fish oil
(10mg)
E: no effect
AMI + death + stroke, fish
oil: ↓ AMI+ death + stroke
Yusuf/HOPE
[61]
The New
England
Journal of
Medicine
DB, PC, 2 × 2
4.5 y
𝑁= 9451; M and F; ≥55 y;
high risk CD patients;
primary and secondary
prevention
E (800mg or 400 IU)
Ramipril
E: no effect AMI +CV
death + stroke; Ramipril:
↓ AMI+CV death + stroke
De Gaetano/PPP
[62] The Lancet
OL, PC, 2 × 2
3.6 y
𝑁= 4495; M and F; mean
64.4 y; high risk CD
patients; primary
prevention
E (300mg)
Aspirin(100mg)
E: no effect
Aspirin: ↓ AMI+CV
death + stroke
Collins et al./
HPSCG
[63]
The Lancet DB, PC5 y
𝑁= 20.563; M and F;
40–80 y; CD, other OAD,
DM patients
C (250mg) + E
(600mg) +𝛽C (20mg) No ↓ 5 y mortality
To¨rnwall et al.
[64]
European
Heart Journal
DB, PC
5–8 y
𝑁= 29.133; all M; 50–69 y;
smokers with risk on MCE
or MI history
E (50mg) or 𝛽C (20mg) or
both
𝛽C: ↑ risk nonfatal MI; E:
no effect
Armitage et al./
HPS
[65]
BMC
Medicine
DB, PC, 2 × 2
5.5 y
𝑁= 20.536; M and F;
40–80 y; high risk CD
patients; primary and
secondary prevention
Simvastatin (40mg)
C (250mg) + E
(600mg) +𝛽C (20mg)
AO: no effect
Cook et al./WACS
[66]
Archives of
Internal
Medicine
DB,PC, 2 × 2
9.4 y
𝑁= 8171; all F; ≥1 CVE in
history, secondary
prevention
C (500mg) + E(600 IU) on
alt days +𝛽C (50mg) on alt
days
No effect AMI +CV
death + stroke +morbidity
Lee et al.
[67]
Journal of
The
American
Medical
Association
DB, PC, 2 × 2
10.1 y
𝑁= 39.876; all F; >45 y,
healthy.
E (600 IU)
Asiprin (100mg)
No benefit for major CV
events. No effect on total
mortality
Lonn/HOPE II
[68]
Journal of
The
American
Medical
Association
DB, PC
7.0 y
𝑁= 3994, >55 y with
vascular disease or DM;
extension of HOPE I trial.
E (400 IU)
No prevention of major
CV events. No prevention
of cancer. Risk of HF may
be ↑.
Kataja-Tuomola
et al. [69]
Annals
Medicine
DB, PC, 2 × 2
6.1 y
𝑁= 29.133, all M smokers,
some with DM.
E (50mg/d)
𝛽C (20mg/d)
No protective effect on
macrovascular outcomes or
total mortality.
Large multicenter studies all presented the same result that oral AOs had no beneficial effect on cardiovascular outcomes. Some studies even showed an
increased risk of coronary heart disease. Population∗:𝑁: number of patients; M: male; F: female; y: age in years; 2×2: 2×2 factorial design comparing placebo,
agent A, agent B, and combination of agent A and B; DB: double blind; PC: placebo controlled; E: vitamin E; C: vitamin C; 𝛽C: beta-carotene; FCHD: fatal
coronary heart disease; MCE: myocardial event; CHD: coronary heart disease; AMI: acute myocardial infarction; CV: cardiovascular; OS: oxidative stress; IU:
international units; HF: heart failure.
properties of each AO should be known to optimize their
application. To be effective, it is imperative that AOs reach
the specific compartments of the cell where ROS are gener-
ated. For many vascular cells, this requires uptake into the
cytoplasm (or vesicles) [2]. Importantly, AOs can become
oxidants in some cellular compartments.
Third, lack of clinical improvement may be attributed to
the selection of the population. Most patients enrolled in the
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clinical trials have already established CVD and in these cases
AO therapy may be too late to be effective since, in animal
studies, most protocols describe administration of AOs prior
to the initiation of the disease. Finally, and perhaps most
important, the choice of AOs should be based on the identity
and location of ROS responsible for pathology. So instead of
experimenting with cocktails of AOs in human trials, basic
research should focus on targeting the specific pathways of
different ROS responsible for the given pathology [112, 119].
The lack of cardiovascular benefit of AOs that are pre-
sently available has initiated research on new andmore effec-
tive compounds. Clinical studies show that while these novel
compounds do not reduce endpoints related to atherosclero-
sis, they improve endothelial function by increasing local NO
bioavailability and therefore endothelium-dependent vasodi-
latation. Promising new agents are NO-donor phenols [120]
and AGI-1067 that inhibits pro-inflammatory gene expres-
sion [121]. Other potentially promising AOs act through tar-
geting NAPDH oxidases, Nox (VAS2870), and Nox2 peptide
(gp91-dstat), preventing eNOS uncoupling or inhibiting xan-
thine oxidase (allopurinol) [2, 72, 119]. Technological devel-
opments also allow discovery of new functions for existing
AOs. For example, oxidative damage ofDNAwas shown to be
repaired in cells by naturally occurring phenols independent
of known DNA repair enzymes thereby entailing possible
new approaches [122].
Moreover, targeting AO therapy at specific sites of ROS
production may be more effective in treatment of cardiovas-
cular disease than global AO therapy [123]. Mitochondrial
ROS scavenging is effective in treating hypertensive rats [124]
and led to the realization that mitochondria play a central
role in the pathogenesis of cardiovascular disease. New
pharmacological approaches enable targeting of therapeutic
substances at the mitochondria [125]. In particular, AOs
conjugated with triphenylphosphonium cation such as mito-
quinone (MitoQ), mitovitamin E, and mitophenyltertbuty-
line achieve much higher concentrations in the mitochon-
drial membrane, than those in the cytosol, due to the negative
membrane potential of the inner mitochondrial membrane
[126]. A new type of compounds, named SkQs, consisting
of an antioxidant moiety (plastoquinone) and a penetrating
cation, has been synthetized. This group of AOs specifically
prevented oxidation of mitochondrial cardiolipin, arrested
H
2
O
2
-induced apoptosis, and blocked necrosis initiated by
ROS [86, 127]. Furthermore, SkQs also appear very promising
in inhibiting the development of age-related diseases [86,
128]. However, so far, no studies have been performed that
target mitochondria in cardiovascular disease in humans.
4. Conclusion
ROS play a dual role in cardiovascular (patho)physiology.
ROS signaling plays an important part in endothelial func-
tion, vascular tone, and cardiac function. Conversely, when
excessively produced, ROS can disrupt cellular signaling and
inflict cellular damage. It thus appears that concentration and
location of ROS are the main determinants of their function.
Due to their very short half-life and technical difficulties
of measuring ROS in vivo, little is known about the “safe
margins” of ROS concentrations in cell signaling. Therefore,
it is difficult to estimate which part of ROS production
contributes to cellular homeostasis and normal physiological
functioning and when ROS production becomes excessive
and thereby detrimental.
Although the deleterious effects of ROS can potentially
be reduced by restoring the imbalance between production
and clearance of ROS through administration of AOs, the
dosage and type of AOs should be tailored to the location and
nature of oxidative stress. Continuous administration of AOs
in vivo can be unfavorable for normal cell signaling which,
at least partially, explains the lack of clinical evidence on the
beneficial actions of AO administration.
New research should focus on matching AO therapy to
oxidant stress present in the cardiovascular system. In vitro
studies are extremely important to obtain knowledge on the
mechanisms of oxidative damage as well as potential repair
mechanisms, and when extrapolated to the in vivo setting
with caution, they are likely to contribute to improve the ther-
apeutic strategies for cardiovascular disease.
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